The FDA has accepted for review the sNDA for roflumilast cream 0.05% for mild to moderate atopic dermatitis in pediatric patients aged 2 to 5 years.

On February 26, 2025, roflumilast cream 0.05% (Zoryve; Arcutis Biotherapeutics) took a step forward on the FDA pipeline, as the federal agency has accepted the topical cream's supplemental new drug ...

ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trials Roflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile ...

Additional research is necessary to further explore the effects of tretinoin 0.05% lotion in patients with severe acne.

Investigators examined the efficacy and safety of tretinoin 0.05% lotion to treat moderate to severe acne in a Hispanic population.

RANDOLPH, N.J.--(BUSINESS WIRE)--Insert after sixth graph of release: Important Safety Information: Refissa 0.05% is a prescription medicine that may reduce fine facial wrinkles and mottled ...